| 符薇薇,陈 洁,陈兴强,林丽娟,吴琳虹,李季芳.不同剂量百令胶囊联合非布司他对慢性肾功能不全伴高尿酸血症患者肾功能及血脂水平的影响[J].,2020,(18):3572-3576 |
| 不同剂量百令胶囊联合非布司他对慢性肾功能不全伴高尿酸血症患者肾功能及血脂水平的影响 |
| Effects of Different Doses of Bailing Capsule Combined with Febuxostat on Renal Function and Blood Lipid Levels in Patients with Chronic Renal Insufficiency with Hyperuricemia |
| 投稿时间：2019-12-29 修订日期：2020-01-24 |
| DOI：10.13241/j.cnki.pmb.2020.18.039 |
| 中文关键词: 肾功能 高尿酸血症 百令胶囊 非布司他 慢性肾功能不全 剂量 |
| 英文关键词: Renal function Hyperuricemia Bailing capsule Febuxostat Chronic renal insufficiency Dose |
| 基金项目:海南省卫生计生行业科研项目（160132027A2121） |
|
| 摘要点击次数: 550 |
| 全文下载次数: 312 |
| 中文摘要: |
| 摘要 目的：探讨不同剂量百令胶囊联合非布司他对慢性肾功能不全（CRF）伴高尿酸血症（HU）肾功能及血脂水平的影响。方法：选取2017年7月至2018年8月三亚市人民医院收治的CRF伴HU患者167例为研究对象，按照数表法随机分为大剂量联合组（n=42）、中剂量联合组（n=42）、小剂量联合组（n=42）和非布司他单用组（n=41），所有研究对象均给予非布司他（40 mg/次，1次/日）治疗，大、中、小剂量联合组再分别给予百令胶囊3g/次、2g/次、1g/次，均3次/日。比较治疗后的临床疗效、治疗前后肾功能指标[血肌酐（Scr）、血尿素氮（BUN）、血尿酸（UA）、血β2微球蛋白（血β2-MG）、尿β2-MG、24 h尿蛋白定量]、血脂指标[甘油三酯（TG）、总胆固醇（TC）、高密度脂蛋白（HDL）、低密度脂蛋白（LDL）]水平以及不良反应。结果：治疗后，大剂量联合组肾功能及高尿酸血症的临床总有效率最优（P＜0.05），其次为中剂量联合组，小剂量联合组和非布司他单用组比较差异无统计学意义（P＞0.05）；各组患者治疗后BUN、Scr、UA、血β2-MG、尿β2-MG、24h尿蛋白定量水平均有不同程度的下降，其中大剂量联合组降低最显著（P＜0.05），小剂量联合组和非布司他单用组比较差异无统计学意义（P＞0.05）；大、中、小剂量联合组患者治疗后TG、TC、LDL均有下降，HDL上升，其中大剂量联合组TG、TC、LDL降低最显著（P＜0.05），HDL升高最显著（P＜0.05）；各组患者不良反应发生率比较无统计学差异（P＞0.05）。结论：大剂量百令胶囊联合非布司他治疗CRF伴HU能改善患者的肾功能和血脂指标，其不良反应发生率较低，但是稍高于其他剂量组，建议临床医师根据患者病情选择合适的剂量。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the effects of different doses of Bailing capsule combined with febuxostat on renal function and blood lipid levels in patients with chronic renal insufficiency (CRF) with hyperuricemia (HU). Methods: 167 patients with CRF with HU who were admitted to Sanya People's Hospital from July 2017 to August 2018 were selected as the study subjects, they were randomly divided into high-dose combination group (n=42), medium-dose combination group (n=42), low-dose combination group (n=42) and febuxostat alone group (n=41) according to the number table method. All subjects were treated with febuxostat (40 mg/time, 1 time/day), the high, medium and low dose groups were given Bailing capsule 3 g/time, 2 g/time and 1 g/time respectively, 3times/day. The clinical efficacy of patients after treatment, renal function indicators before and after treatment [serum creatinine (Scr), blood urea nitrogen (BUN), serum uric acid (UA), urine protein index (urine β2 microglobulin (urine β2-MG), blood β2 microglobulin (blood β2-MG), 24 h urine protein quantitation], blood lipid indicators [triglyceride (TG), total cholesterol (TC), high density lipoprotein (HDL) and low density lipoprotein (LDL)] levels and adverse reactions were compared. Results: After treatment, the high-dose combination group had the best improvement in renal function and hyperuricemia, followed by the medium-dose group (P＜0.05). There was no significant difference between the low-dose combination group and the febuxostat alone group(P＞0.05). The levels of BUN, Scr, UA, urinary β2-MG, blood β2-MG, and 24 h urinary protein were decreased in different groups, and the high-dose combination group was significantly lower (P＜0.05). There was no significant difference between the low-dose group and the febuxostat alone group (P＞0.05). After treatment, TG, TC and LDL decreased in high, medium and low dose groups, and HDL increased. Among them, TG, TC and LDL in the high-dose combination group decreased most significantly (P＜0.05), and HDL increased most significantly (P＜0.05). There was no significant difference in the incidence of adverse reactions among the groups (P＞0.05). Conclusion: High-dose Bailing capsule combined with febuxostat in the treatment of CRF with HU can significantly improve the renal function and blood lipid index, and it has good clinical efficacy, the incidence of adverse reactions was low, but slightly higher than other dose groups, recommended that clinicians choose the appropriate dose according to the patient's condition. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
